Clinical outcomes after swicth from etanercept to etanercept biosimilar (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthrits:- DANBIO registry study
Latest Information Update: 03 Mar 2020
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Joint disorders; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen
- 28 Feb 2020 Results evaluating hepatobiliary adverse events after the treatment of Biosimilar Etanercept compare to Etanercept in more then 5000 patients, published in the Annals of the Rheumatic Diseases
- 05 Nov 2018 Results assessing treatment outcomes in Etanercept-treated patients who switched to the Biosimilar Etanercept or maintained Etanercept, published in the Annals of the Rheumatic Diseases
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism